New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 5, 2014
13:02 EDTARWR, RHHBY, BMY, MRK, NVSAnalyst: Arrowhead Research could be in early stages of major run, Barron's says
RBC analyst Michael Yee believes Arrowhead Research is in the early innings of a potentially major run, according to Barron's. Yee cites the company's promising lead drug for Hep B, its RNAi platform technology, and the fact that it could partner with larger firms such as Roche (RHHBY), Bristol Myers (BMY), Merck (MRK), and Novartis (NVS).Reference Link
News For ARWR;RHHBY;BMY;MRK;NVS From The Last 14 Days
Check below for free stories on ARWR;RHHBY;BMY;MRK;NVS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
September 25, 2014
05:28 EDTNVSNovartis AIN457 meets primary endpoint in two Phase III studies
Subscribe for More Information
September 24, 2014
10:58 EDTRHHBYRoche to host conference call
Conference call to discuss new clinical data on Roche's oncology products and pipeline that were presented at the European Society for Medical Oncology's Annual Meeting will be held on September 29 at 4 am. Webcast Link
September 23, 2014
12:10 EDTBMYBristol-Myers to build 650,000 square foot campus in Lawrenceville, NJ
Subscribe for More Information
07:33 EDTMRKOphthotech names Michael Atieh as EVP, Chief Financial and Business Officer
Ophthotech Corporation (OPHT) announced that Michael G. Atieh has been named EVP, Chief Financial and Business Officer and Treasurer effective September 30. Atieh replaces Bruce A. Peacock, Chief Financial and Business Officer and Treasurer, who has notified the company of his intention to retire effective September 30. Atieh spent the majority of his career in the pharmaceutical industry with Merck and Co (MRK), where he held various senior level positions over a 20 year period including Senior Vice President-Merck Medco Managed Care, Vice President-U.S. Human Health, Vice President-Public Affairs, Vice President-Government Relations, and Treasurer.
September 22, 2014
19:23 EDTRHHBYRoche management to meet with JPMorgan
Subscribe for More Information
16:07 EDTNVSAnacor announces commercial launch of KERYDIN topical solution in U.S.
Subscribe for More Information
13:53 EDTRHHBYRoche launches $5.75B bond to back InterMune acquisition, Reuters reports
Subscribe for More Information
07:21 EDTBMYEBD Group to hold a conference
Subscribe for More Information
06:51 EDTMRKMerck to host conference call
Subscribe for More Information
September 20, 2014
15:43 EDTRHHBYInterMune reports MOU in connection with consolidated Delaware action
Subscribe for More Information
September 18, 2014
08:48 EDTMRKNeogen's dairy genomic program to be marketed by Merck
Subscribe for More Information
September 17, 2014
14:54 EDTARWRArrowhead Research November volatility elevated into Phase IIb trial data
Subscribe for More Information
11:00 EDTRHHBYRoche CEO rules out megadeals, focused on bolt-on acquisitions, WSJ says
Roche CEO Severin Schwan said the company won't change its acquisition strategy following the recent deals made or abandoned in the pharmaceutical sector, reports the Wall Street Journal. In an interview with WSJ, Shwan said, "We have been very consistent in our approach to M&A." Regarding transformational deal-making, he said, "We have no intention to do that, whatever happens in the industry." Reference Link
09:33 EDTMRKMerck announced positive results from Phase 3 data for omarigliptin
Subscribe for More Information
08:31 EDTMRKMerck, Sun Pharma enter into licensing agreement for Tildrakizumab
Merck and Sun Pharmaceutical Industries, through their respective subsidiaries,announced an exclusive worldwide licensing agreement for Merck’s investigational therapeutic antibody candidate, tildrakizumab, which is currently being evaluated in Phase 3 registration trials for the treatment of chronic plaque psoriasis, a skin ailment. Under terms of the agreement, Sun Pharma will acquire worldwide rights to tildrakizumab for use in all human indications from Merck in exchange for an upfront payment of $80M. Merck will continue all clinical development and regulatory activities, which will be funded by Sun Pharma. Upon product approval, Sun Pharma will be responsible for regulatory activities, including subsequent submissions, pharmacovigilance, post approval studies, manufacturing and commercialization of the approved product. Merck is eligible to receive undisclosed payments associated with regulatory and sales milestones, as well as tiered royalties ranging from mid-single digit through teen percentage rates on sales. The transaction is subject to customary closing conditions, including the requirements under the Hart Scott-Rodino Antitrust Improvements Act.
07:43 EDTRHHBY, BMYBofA/Merrill to hold a conference
Subscribe for More Information
07:36 EDTARWRArrowhead outlook positive, says RBC Capital
Subscribe for More Information
September 16, 2014
07:31 EDTRHHBY, NVS, MRKEuropean Association for Study of Diabetes to hold annual meeting
50th Annual Meeting of EASD to be held in Vienna, Austria on September 15-19.
07:25 EDTMRKMerck price target raised to $72 from $62 at SunTrust
After meeting with Merck's CEO and head of clinical development, SunTrust increased its price target on the company as the firm thinks that it is ideally positioned across five of the fastest growing therapeutic classes. The firm believes that the company's EPS growth rates from 2015-2020 will be three percentage points above Street estimates, while it has a first-mover advantage in oncology. It keeps a Buy rating on the shares.
06:00 EDTBMYBristol-Myers announces Health Canada approval of Yervoy
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use